These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36340307)

  • 1. Lysosomal Acid Lipase Activity in Non-alcoholic Fatty Liver Disease as a Novel Diagnostic and Therapeutic Target: A Systematic Literature Review of Current Evidence and Future Directions.
    Bashir A; Duseja A; Verma A; De A; Tiwari P
    J Clin Exp Hepatol; 2022; 12(6):1535-1546. PubMed ID: 36340307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease?
    Baratta F; Pastori D; Ferro D; Carluccio G; Tozzi G; Angelico F; Violi F; Del Ben M
    World J Gastroenterol; 2019 Aug; 25(30):4172-4180. PubMed ID: 31435171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver Disease.
    Baratta F; Pastori D; Del Ben M; Polimeni L; Labbadia G; Di Santo S; Piemonte F; Tozzi G; Violi F; Angelico F
    EBioMedicine; 2015 Jul; 2(7):750-4. PubMed ID: 26288848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme replacement therapy in lysosomal acid lipase deficiency (LAL-D): a systematic literature review.
    Bashir A; Tiwari P; Duseja A
    Ther Adv Rare Dis; 2021; 2():26330040211026928. PubMed ID: 37181111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic cholesteryl ester accumulation in lysosomal acid lipase deficiency: non-invasive identification and treatment monitoring by magnetic resonance.
    Thelwall PE; Smith FE; Leavitt MC; Canty D; Hu W; Hollingsworth KG; Thoma C; Trenell MI; Taylor R; Rutkowski JV; Blamire AM; Quinn AG
    J Hepatol; 2013 Sep; 59(3):543-9. PubMed ID: 23624251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of non-alcoholic fatty liver disease.
    Baratta F; Pastori D; Tozzi G; D'Erasmo L; Di Costanzo A; Arca M; Ettorre E; Ginanni Corradini S; Violi F; Angelico F; Del Ben M
    Liver Int; 2019 Dec; 39(12):2301-2308. PubMed ID: 31392821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The global prevalence and genetic spectrum of lysosomal acid lipase deficiency: A rare condition that mimics NAFLD.
    Carter A; Brackley SM; Gao J; Mann JP
    J Hepatol; 2019 Jan; 70(1):142-150. PubMed ID: 30315827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced lysosomal acid lipase activity - A potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients.
    Selvakumar PK; Kabbany MN; Lopez R; Tozzi G; Alisi A; Alkhouri N; Nobili V
    Dig Liver Dis; 2016 Aug; 48(8):909-13. PubMed ID: 27198736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low levels of Lysosomal Acid Lipase (LAL) activity increases necroinflammation in adult patients with biopsy-proven metabolic associated fatty liver disease.
    Thoen RU; Longo L; Neto SC; Álvares-da-Silva MR
    Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101638. PubMed ID: 33662773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Lysosomial Acid Lipase Reduction Play a Role in Adult Non-Alcoholic Fatty Liver Disease?
    Baratta F; Pastori D; Polimeni L; Tozzi G; Violi F; Angelico F; Del Ben M
    Int J Mol Sci; 2015 Nov; 16(12):28014-21. PubMed ID: 26602919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Relative Deficiency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver Disease.
    Tovoli F; Napoli L; Negrini G; D'Addato S; Tozzi G; D'Amico J; Piscaglia F; Bolondi L
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28587063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced Lysosomal Acid Lipase Activity in Blood and Platelets Is Associated With Nonalcoholic Fatty Liver Disease.
    Ferri F; Mischitelli M; Tozzi G; Messina E; Mignini I; Mazzuca S; Pellone M; Parisse S; Marrapodi R; Visentini M; Baratta F; Del Ben M; Pastori D; Perciballi R; Attilia ML; Carbone M; De Santis A; Violi F; Angelico F; Ginanni Corradini S
    Clin Transl Gastroenterol; 2020 Feb; 11(2):e00116. PubMed ID: 32463622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ménage à trois of autophagy, lipid droplets and liver disease.
    Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
    Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysosomal Acid Lipase: Can it be a New Non-Invasive Serum Biomarker of Cryptogenic Liver Fibrosis and Cirrhosis?
    Gravito-Soares M; Gravito-Soares E; Gomes D; Tome L
    Ann Hepatol; 2019; 18(1):78-88. PubMed ID: 31113613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A human liver chimeric mouse model for non-alcoholic fatty liver disease.
    Bissig-Choisat B; Alves-Bezerra M; Zorman B; Ochsner SA; Barzi M; Legras X; Yang D; Borowiak M; Dean AM; York RB; Galvan NTN; Goss J; Lagor WR; Moore DD; Cohen DE; McKenna NJ; Sumazin P; Bissig KD
    JHEP Rep; 2021 Jun; 3(3):100281. PubMed ID: 34036256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low Serum Lysosomal Acid Lipase Activity Correlates with Advanced Liver Disease.
    Shteyer E; Villenchik R; Mahamid M; Nator N; Safadi R
    Int J Mol Sci; 2016 Feb; 17(3):312. PubMed ID: 26927097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spleen dimensions are inversely associated with lysosomal acid lipase activity in patients with non-alcoholic fatty liver disease.
    Polimeni L; Pastori D; Baratta F; Tozzi G; Novo M; Vicinanza R; Troisi G; Pannitteri G; Ceci F; Scardella L; Violi F; Angelico F; Del Ben M
    Intern Emerg Med; 2017 Dec; 12(8):1159-1165. PubMed ID: 28900817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic changes and propensity for inflammation, fibrosis, and cancer in livers of mice lacking lysosomal acid lipase.
    Bradić I; Liesinger L; Kuentzel KB; Vujić N; Trauner M; Birner-Gruenberger R; Kratky D
    J Lipid Res; 2023 Sep; 64(9):100427. PubMed ID: 37595802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.